Major interaction on record — check this product against your medications before combining. Check your meds →
Dietary supplement

Legs Relax Ingredients & Drug Interactions

by Herbal Terra

Liquid Category: Botanical
Most serious interaction: Major
The interaction bottom line Most serious interaction: Major

Legs Relax is a dietary supplement by Herbal Terra with 3 active ingredients. Its ingredients are commonly taken for cough and respiratory congestion, sore throat, digestive upset.Based on those ingredients, 1,141 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Valerian Root Extract, Dry, Quina Bark Extract, Dry, Thyme Leaf Extract, Dry. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Legs Relax by Herbal Terra

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 3 active ingredients.
  • “Proprietary Extract Blend” is a proprietary blend — the label gives one combined amount (983 mg) without saying how much of each component you get.

Legs Relax contains three active herbal extracts in a liquid form: Thyme Leaf Extract, Valerian Root Extract, and Quina Bark Extract (cinchona). The liquid also contains alcohol, water, and glycerin as inactive ingredients.

The first ingredient is listed as a proprietary extract blend, meaning the exact proportions of the three actives aren't disclosed on the label.

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use.

Why this rating?
  • The label markets this product for: Leg relaxation and comfort support.
  • We looked for evidence on: Leg cramps, Muscle cramps, Restless legs syndrome (RLS), Leg tension, Restlessness.
  • The closest evidence on file: Cinchona is rated "Insufficient Reliable Evidence To Rate" for Muscle cramps (Natural Medicines).
  • Also on file: Cinchona is rated "Insufficient Reliable Evidence To Rate" for Leg cramps.
  • Also on file: Valerian is rated "Insufficient Reliable Evidence To Rate" for Restless legs syndrome (RLS).

The evidence supporting these ingredients is thin. Thyme leaf extract has insufficient reliable evidence to rate it for bronchitis, aging skin, alopecia areata, or common cold.

Valerian root shows possibly effective evidence for insomnia, but insufficient evidence for restless legs syndrome, pre-procedural anxiety, stress, or dysmenorrhea. Quina bark (cinchona) lacks sufficient evidence for cancer, respiratory infections, hemorrhoids, influenza, malaria, or muscle cramps.

If you're considering this for a specific condition, ask your pharmacist whether the science supports what you're trying to treat.

The evidence, ingredient by ingredient Thyme Valerian Cinchona

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 3 of the 3 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 3 of 3.
  • General safety write-ups exist for 3 of 3.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Thyme leaf extract is generally well tolerated when taken by mouth, though some people report allergic reactions, diarrhea, dizziness, headache, heartburn, nausea, or vomiting. Food amounts are likely fine, but medicinal doses should be avoided unless approved by your doctor.

Valerian root is generally well tolerated short-term, but long-term safety isn't well studied. Common side effects include dizziness, drowsiness, and mental slowness; headache, stomach upset, excitability, and vivid dreams have also been reported.

If you stop valerian suddenly after extended use, you may experience withdrawal symptoms like rapid heartbeat, anxiety, or insomnia — taper slowly. Quina bark is the most concerning: it contains quinine, which can cause serious side effects including rare but dangerous blood disorders, heart rhythm problems, and ringing ears.

The product is not dose-controlled. All three ingredients should be avoided in pregnancy.

Valerian is unsafe in pregnancy; quina bark is likely unsafe. Neither should be used while breastfeeding — valerian data is insufficient; quinine passes into breast milk.

Side effects, ingredient by ingredient Thyme Valerian Cinchona

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 3 of the 3 matched ingredients can interact with medications — Cinchona, Thyme, Valerian.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: anticoagulant / antiplatelet drugs; heart-rhythm medications.
  • For scale: 1,142 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check with your pharmacist before taking Legs Relax if you're on quinidine or quinine (heart rhythm drugs) — these are Major-severity interactions and can be dangerous. Also double-check if you take QT-prolonging heart drugs, blood thinners or antiplatelet drugs, seizure medications (carbamazepine, phenobarbital), antacids, drugs affecting acetylcholine signaling, central nervous system depressants (sedatives, alcohol, benzodiazepines), or any drug metabolized through glucuronidation or CYP2D6.

The medication checker below can verify your exact prescriptions.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with no established evidence rating for its marketed use. Major medication interactions have been identified, and safety information is well characterized.

This product carries significant medication interactions, especially with heart medications, blood thinners, seizure drugs, and sedating drugs. The evidence for effectiveness is weak across most of the conditions it might be marketed for.

If you take any prescription medications, check them against this product's drug interactions before starting. Talk to your pharmacist about whether the ingredients match what you're trying to treat and whether it's safe for your individual situation.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 3 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Sep 25, 2025.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Legs Relax, straight from the product label.

Brand Herbal Terra
Barcode (UPC) 7439500427421
Net contents 2 Fluid Ounce(s); 60 mL
Market status On market
Date entered into DSLD Sep 25, 2025
DSLD ID 325167
Product type Botanical
Supplement form Liquid
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Gluten Free, Sugar Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Legs Relax by Herbal Terra, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 mL
Maximum serving Sizes:
1 mL
Servings per container
60
UPC/BARCODE
7439500427421
IngredientAmount% DV
Proprietary Extract Blend983 mg--
Thyme Leaf Extract, Dry0 NP--
Valerian Root Extract, Dry0 NP--
Quina Bark Extract, Dry0 NP--

Other ingredients: Alcohol, Water, Glycerin

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions

Shake well before use. Adults take up to 30 drops (1 mL, one full squeeze of the dropper bulb) in 3-4 fl. oz. of juice or water up to 4 times a day.

Precautions

We recommend to seek expert medical advice before taking. May have contraindications and cause adverse reaction.

Consult a physician before giving to children under 18, before using during pregnancy, if nursing, or if you are on any medications.

Consult a physician before giving to children under 18, before using during pregnancy, if nursing, or if you are on any medications. Keep out of the reach of children!

Do not use if you are allergic to any ingredients.

Storage

Store in a cool, dry, dark place.

FDA Disclaimer Statement

This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent any disease.

Formulation

cGMP Made in compliance with cGMP 21 CFR 111 in an FDA registered and inspected facility.

Sugar free

Expertly extracted 100% natural Premium product

Organic alcohol

No artificial ingredients, color additives, fillers or binders.

Natural Gluten free

Formula

Organic alcohol

FDA Statement of Identity

Herbal Supplement

Seals/Symbols

Made in USA

General Statements

Extraction rate: about 1/3-4 (up to 333 mg of dry raw material per 1 ml of extract).

See for yourself

Legs Relax by Herbal Terra label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Legs Relax by Herbal Terra

These are the 3 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 mL Dosage formLiquid Servings per container60 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Extract Blend

983 mg per serving

Other (inactive) ingredients: Alcohol, Water, Glycerin. These complete the product’s ingredient list but are not active constituents.

Interaction report

Legs Relax by Herbal Terra Drug Interactions

Want to check YOUR meds against Legs Relax?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,141Drugs
3 Major 818 Moderate 320 Minor

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Legs Relax with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Valerian Root Extract, Dry6 drug types · 902 drugs

Alcohol (Ethanol)

Valerian can have additive sedative effects when used concomitantly with alcohol.
Valerian has sedative effects. Theoretically, valerian might have an additive sedative effect when combined with alcohol. Excessive sedation has been reported in an alcohol-abusing individual who took valerian and Gingko biloba. However, the potential interaction between valerian and alcohol has been disputed in other research. Limited evidence suggests that a combination of valerian 160 mg and lemon balm 80 mg (Euvegal) does not cause further deterioration in reaction ability and reaction rate when taken with alcohol as compared to the effects of alcohol alone.

Likelihood Possible Evidence B
Alprazolam (Xanax)

Valerian can have additive sedative effects when used with alprazolam. Also, valerian in high doses might modestly increase alprazolam levels, though this is not likely to be clinically significant.
Valerian has sedative effects. Theoretically, valerian might cause additive sedation when combined with alprazolam. Also, a small pharmacokinetic study shows that taking valerian extract 1000 mg daily (providing 11 mg valerenic acid) might increase alprazolam levels by about 19%. This might be due to valerian's mild inhibition of cytochrome P450 3A4 (CYP3A4). Despite being statistically significant, this increase is not likely to be clinically significant.

Likelihood Possible Evidence B
Cns Depressants

Valerian can have additive sedative effects when used concomitantly with CNS depressant drugs.
Theoretically, concomitant use of valerian and drugs with sedative and anesthetic properties may cause additive therapeutic and adverse effects.

Likelihood Possible Evidence D
Glucuronidated Drugs

Valerian might weakly inhibit glucuronidation and increase concentrations of drugs metabolized by UGT1A1 and UGT2B7.
In vitro research shows that methanolic valerian extract and valerenic acid might competitively inhibit UDP-glucuronosyltransferase (UGT) 1A1 (UGT1A1) and UGT2B7.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Valerian does not seem to have a clinically relevant effect on levels of drugs metabolized by CYP2D6.
Although some in vitro evidence suggests that valerian affects CYP2D6, clinical pharmacokinetic (PK) studies show that valerian is unlikely to affect the CYP2D6 enzyme. In one PK study, taking valerian 1000 mg (providing about 11 mg valerenic acid) nightly for 14 days did not affect the metabolism of dextromethorphan, a CYP2D6 substrate. In another PK study, taking valerian 125 mg three times daily for 28 days did not affect metabolism of debrisoquine, an accepted CYP2D6 probe-substrate.

Likelihood Unlikely Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Valerian does not seem to have a clinically relevant effect on levels of drugs metabolized by CYP3A4.
Although some in vitro evidence suggests that valerian extract might inhibit or induce CYP3A4, clinical pharmacokinetic (PK) studies show that valerian does not have a clinically significant effect on the CYP3A4 enzyme. In one PK study, taking valerian 125 mg three times daily for 28 days did not affect metabolism of midazolam, an accepted CYP3A4 probe-substrate. In another PK study, taking valerian 1000 mg (providing about 11 mg valerenic acid) nightly for 14 days modestly increases levels of alprazolam, a CYP3A4 substrate, suggesting mild inhibition of CYP3A4. However, this mild inhibition is unlikely to be clinically relevant.

Likelihood Possible Evidence B

Quina Bark Extract, Dry11 drug types · 492 drugs

Quinidine

Theoretically, taking cinchona might increase plasma levels and adverse effects of quinidine.
Cinchona contains quinidine.

Likelihood Probable Evidence D
Quinine

Theoretically, taking cinchona might increase plasma levels and adverse effects of quinine.
Cinchona contains quinine.

Likelihood Probable Evidence D
Antacids

Theoretically, taking cinchona might decrease the effectiveness of antacids. Theoretically, taking antacids might also increase the risk of adverse effects from cinchona.
Some research shows that taking cinchona lowers stomach acid pH. In addition, some research shows that taking antacids might increase urinary pH. Theoretically, this may increase the amount of quinidine, a constituent of cinchona, reabsorbed in the renal tubules and increase the risk of quinidine toxicity.

Likelihood Possible Evidence D
Anticoagulant/Antiplatelet Drugs

Theoretically, taking cinchona might increase the drug effects and risk of bleeding with anticoagulant and antiplatelet drugs.
In vitro evidence shows that the alkaloids quinine, quinidine, and cinchonine, constituents of cinchona, inhibit platelet aggregation.

Likelihood Possible Evidence D
Carbamazepine (Tegretol)

Theoretically, taking cinchona might increase the adverse effects of carbamazepine.
Clinical research shows that taking quinine, a constituent of cinchona, increases the peak plasma concentration and area under the curve of carbamazepine.

Likelihood Probable Evidence B
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, taking cinchona might inhibit cytochrome P450 2D6 (CYP2D6) and increase levels of drugs metabolized by this enzyme.
Quinidine, a constituent of cinchona, inhibits CYP2D6-mediated metabolism in humans.

Likelihood Possible Evidence D
Digoxin (Lanoxin)

Theoretically, taking cinchona might increase serum levels of digoxin.
Quinine and quinidine, which are constituents of cinchona, decrease clearance of digoxin and increase serum digoxin levels in humans.

Likelihood Possible Evidence D
Phenobarbital (Luminal)

Theoretically, taking cinchona might increase the adverse effects of phenobarbital.
Clinical research shows that taking quinine, a constituent of cinchona, increases the peak plasma concentration and area under the curve of phenobarbital.

Likelihood Probable Evidence D
Qt Interval-Prolonging Drugs

Theoretically, taking cinchona with other QT interval-prolonging drugs might cause an additive effect and increase the risk of ventricular arrhythmias.
Quinidine and quinine, which are constituents of cinchona, prolong the QT interval.

Likelihood Possible Evidence D
H2-Blockers

Theoretically, taking cinchona might decrease the effectiveness of H2-blockers.
Some research shows that taking cinchona lowers stomach acid pH.

Likelihood Possible Evidence D
Proton Pump Inhibitors (Ppis)

Theoretically, taking cinchona might decrease the effectiveness of PPIs.
Some research shows that taking cinchona lowers stomach acid pH.

Likelihood Possible Evidence D

Thyme Leaf Extract, Dry4 drug types · 379 drugs

Anticholinergic Drugs

Theoretically, concurrent use of anticholinergic drugs and thyme essential oil might reduce the effects of anticholinergic drugs.
In vitro evidence suggests that thyme essential oil and specific essential oil constituents like thymohydroquinone and carvacrol can inhibit acetylcholinesterase (AChE). However, this effect has not been observed in humans.

Likelihood Possible Evidence D
Anticoagulant/Antiplatelet Drugs

Theoretically, thyme leaf extract might have additive effects with anticoagulant or antiplatelet drugs.
In vitro and animal research suggests that thyme leaf extract has antiplatelet effects. However, this effect has not been observed in humans.

Likelihood Possible Evidence D
Cholinergic Drugs

Theoretically, concurrent use of cholinergic drugs and thyme essential oil might cause additive cholinergic effects.
In vitro evidence suggests that thyme essential oil and specific essential oil constituents like thymohydroquinone and carvacrol can inhibit acetylcholinesterase (AChE). However, this effect has not been observed in humans.

Likelihood Possible Evidence D
Estrogens

Theoretically, thyme might competitively inhibit the effects of estrogen replacement therapy.
In vitro research shows that thyme has estrogen receptor-binding activity and phytoestrogen content. However, this effect has not been observed in humans.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Legs Relax, from the product label.

Herbal Terra

See all Herbal Terra products
Name
Herbal Terra LLC
Phone Number
+18083857868
Web Address
herbalterra.com
Pharmacist Counseling Corner

Legs Relax by Herbal Terra: Common Questions

Does Legs Relax by Herbal Terra interact with any medications?
Yes. Based on its ingredients, Legs Relax has a known interaction with 1,141 medications, including 3 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Legs Relax contains 3 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is this safe to take during pregnancy?
No. Quina bark is likely unsafe in pregnancy because of quinine's potential to harm the pregnancy. Valerian is also unsafe during pregnancy. Thyme in food amounts is likely safe, but medicinal amounts lack sufficient safety data. Do not take this product if you're pregnant without approval from your doctor.
Can I breastfeed while using Legs Relax?
The safety data advises against it. Quinine (in Quina Bark) passes into breast milk and hasn't been proven safe for babies. Valerian also hasn't been adequately studied for breastfeeding safety. Talk with your doctor or pharmacist about whether this product is appropriate for you.
What are the most common side effects?
Thyme may cause dizziness, headache, nausea, heartburn, or diarrhea. Valerian commonly causes drowsiness, dizziness, and mental slowness, plus headache or upset stomach in some people. Quina bark can cause nausea, vomiting, diarrhea, and ringing in the ears. If you have any of these, stop and contact your pharmacist.
Does it really help with restless legs?
We don't have strong evidence in our data. Valerian is possibly effective for insomnia, but there's only insufficient evidence for restless legs syndrome. If that's what you're hoping to treat, ask your pharmacist about options with better-established evidence.
What's the alcohol content, since it's a liquid?
Alcohol is listed as an inactive ingredient in the liquid base. Exact concentration isn't specified in the product facts. If you need to avoid alcohol entirely, check the label or contact the manufacturer directly.
Can I use this long-term?
Valerian's long-term safety isn't well studied, and stopping it abruptly after extended use can cause withdrawal symptoms like anxiety and insomnia. Thyme food amounts are generally safe, but medicinal doses are less clear. Quina bark carries risks with prolonged high-dose use. Long-term use isn't advised without close supervision from your pharmacist or doctor.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Legs Relax is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Legs Relax label
Sources

Sources & How We Checked

Legs Relax's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 70 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Thyme 18 references
  1. Zava DT, Dollbaum CM, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 1998;217:369-78. PubMed
  2. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  3. Okazaki K, Kawazoe K, Takaishi Y. Human platelet aggregation inhibitors from thyme (Thymus vulgaris L.). Phytother Res 2002;16:398-9. .
  4. Spiewak R, Skorska C, Dutkiewicz J. Occupational airborne contact dermatitis caused by thyme dust. Contact Dermatitis 2001;44:235-9. . PubMed
  5. Ernst E, Marz R, Sieder C. A controlled multi-centre study of herbal versus synthetic secretolytic drugs for acute bronchitis. Phytomedicine 1997;4:287-93. PubMed
  6. Yamamoto J, Yamada K, Naemura A, et al. Testing various herbs for antithrombotic effect. Nutrition 2005;21(5):580-7. PubMed
  7. Tognolini, M., Barocelli, E., Ballabeni, V., Bruni, R., Bianchi, A., Chiavarini, M., and Impicciatore, M. Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity. Life Sci. 2-23-2006;78(13):1419-1432. PubMed
  8. Mackiewicz, B., Skorska, C., Dutkiewicz, J., Michnar, M., Milanowski, J., Prazmo, Z., Krysinska-Traczyk, E., and Cisak, E. Allergic alveolitis due to herb dust exposure. Ann Agric Environ Med 1999;6(2):167-170.
  9. Martinez-Gonzalez, M. C., Goday Bujan, J. J., Martinez, Gomez W., and Fonseca, Capdevila E. Concomitant allergic contact dermatitis due to Rosmarinus officinalis (rosemary) and Thymus vulgaris (thyme). Contact Dermatitis 2007;56(1):49-50.
  10. Jukic, M., Politeo, O., Maksimovic, M., Milos, M., and Milos, M. In vitro acetylcholinesterase inhibitory properties of thymol, carvacrol and their derivatives thymoquinone and thymohydroquinone. Phytother.Res 2007;21(3):259-261.
  11. Marzian, O. [Treatment of acute bronchitis in children and adolescents. Non-interventional postmarketing surveillance study confirms the benefit and safety of a syrup made of extracts from thyme and ivy leaves]. MMW.Fortschr.Med 6-28-2007;149(27-28 Suppl
  12. Cuzzolin, L. and Benoni, G. Attitudes and knowledge toward natural products safety in the pharmacy setting: an Italian study. Phytother.Res 2009;23(7):1018-1023. PubMed
  13. Berova, N., Stransky, L., and Krasteva, M. Studies on contact dermatitis in stomatological staff. Dermatol.Monatsschr. 1990;176(1):15-18.
  14. Smeenk, G., Kerckhoffs, H. P., and Schreurs, P. H. Contact allergy to a reaction product in Hirudoid cream: an example of compound allergy. Br.J Dermatol. 1987;116(2):223-231.
  15. Le Roy, R., Grosshans, E., and Foussereau, J. [Investigation of contact allergies in 100 cases of ulcus cruris (author's transl)]. Derm.Beruf.Umwelt. 1981;29(6):168-170.
  16. Lorenzi, S., Placucci, F., Vincenzi, C., Bardazzi, F., and Tosti, A. Allergic contact dermatitis due to thymol. Contact Dermatitis 1995;33(6):439-440. PubMed
  17. Bahadoran P, Rokni FK, Fahami F. Investigating the therapeutic effect of vaginal cream containing garlic and thyme compared to clotrimazole cream for the treatment of mycotic vaginitis. Iran J Nurs Midwifery Res 2010;15(Suppl 1):343-9.
  18. Erol S, Aydin B, Dilli D, Okumus N, Zenciroglu A, Gündüz M. An interesting newborn case of fructose 1-6 diphosphatase deficiency triggered after thyme juice ingestion. Clin Lab. 2014;60(1):151-3. PubMed

See these in context on the Thyme monograph →

Valerian 37 references
  1. Willey LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: a case report. Vet Hum Toxicol 1995;37:364-5.
  2. Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on "reaction time, alertness and concentration" in volunteers. Pharmacopsychiatry 1999;32:235-41. PubMed
  3. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999;56:125-38. PubMed
  4. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999;51:505-12. PubMed
  5. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with Valerian root withdrawal. [Letter to the Editor]. JAMA 1998;280:1566-7. PubMed
  6. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. PubMed
  7. MacGregor FB, Abernethy VE, Dahabra S, et al. Hepatotoxicity of herbal remedies. BMJ 1989;299:1156-7. PubMed
  8. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985;2:144-8. PubMed
  9. Hadley S, Petry JJ. Valerian. Am Fam Physician 2003;67:1755-8..
  10. Glass JR, Sproule BA, Herrmann N, et al. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 2003;23:260-8. PubMed
  11. Lefebvre T, Foster BC, Drouin CE, et al. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharmaceut Sci 2004;7:265-73.
  12. Yuan CS, Mehendale S, Xiao Y, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 2004;98:353-8. PubMed
  13. Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32:1333-6. PubMed
  14. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77:415-26. PubMed
  15. Gutierrez S, Ang-Lee MK, Walker DJ, Zacny JP. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol Biochem Behav 2004;78:57-64. PubMed
  16. Jacobs BP, Bent S, Tice JA, et al. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore) 2005;84:197-207. PubMed
  17. National Toxicology Program, US Department of Health and Human Services. Chemical Information Review Document for Valerian (Valeriana officinalis L.) [CAS No. 8057-49-6] and Oils [CAS No. 8008-88-6]. Supporting Nomination for Toxicological Evaluation by t
  18. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010 Jun;11:505-11. PubMed
  19. Coxeter PD, Schluter PJ, Eastwood HL, et al. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement Ther Med. 2003 Dec;11:215-22. PubMed
  20. Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res. 2004 Oct;18:831-6. PubMed
  21. Cuellar NG, Ratcliffe SJ. Does valerian improve sleepiness and symptom severity in people with restless legs syndrome? Altern Ther Health Med 2009;15:22-8.
  22. Chen D, Klesmer J, Giovanniello A, et al. Mental status changes in an alcohol abuser taking valerian and gingko biloba. Am J Addict. 2002 Winter;11:75-7. PubMed
  23. Albrecht M, Berger W, Laux P, Schmidt U, et al. Psychopharmaka und Verkehrssicherheit. Der Einfluß von Euvegal® - Dragees forte auf die Fahrtüchtigkeit und Kombinationswirkungen mit Alkohol Z Allg Med 1995;71:1215-25.
  24. Carrasco MC, Vallejo JR, Pardo-de-Santayana M, et al. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res. 2009 Dec;23:1795-6.
  25. Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol. 2007 Nov;101:350-8.
  26. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol. 2007 Jan;100:23-30. PubMed
  27. Alkharfy, K. M. and Frye, R. F. Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro. Xenobiotica 2007;37(2):113-123.
  28. Vassiliadis, T., Anagnostis, P., Patsiaoura, K., Giouleme, O., Katsinelos, P., Mpoumponaris, A., and Eugenidis, N. Valeriana hepatotoxicity. Sleep Med 2009;10(8):935. PubMed
  29. Muller, Z., Sarkany, A., Altorjay, A., Szilagyi, A., Tura, T., and Ozsvar, Z. [Liver failure a la Eastern Europe]. Orv.Hetil. 3-22-2009;150(12):555-557. PubMed
  30. National Toxicology Program, US Department of Health and Human Services. Chemical Information Review Document for Valerian (Valeriana officinalis L.) [CAS No. 8057-49-6] and Oils [CAS No. 8008-88-6]. 2009;
  31. Wells SR. International intravenous administration of a crude valerian root extract. NACCT 1995;33:542.
  32. Aydinoglu U, Özcan H, Yücel A, Yücel N, Mutlu M. Valerian induced hypomania: a case report. Bull Clin Psychopharma 2012;22(Suppl. 1):S63.
  33. Mirabi P, Mojab F. The effects of valerian root on hot flashes in menopausal women. Iran J Pharm Res 2013;12(1):217-22.
  34. Thomas K, Canedo J, Perry PJ, et al. Effects of valerian on subjective sedation, field sobriety testing and driving simulator performance. Accid Anal Prev. 2016 Jul;92:240-4. PubMed
  35. Kia YH, Alexander S, Dowling D, Standish R. A case of steroid-responsive valerian-associated hepatitis. Intern Med J. 2016 Jan;46(1):118-9. PubMed
  36. Burke H, Jiang S, Chatham P, Stern TA. Delirium After Withdrawal From Valerian Root: A Case Report. Psychosomatics. 2020;61(6):787-790. PubMed
  37. Hajizadeh I, Jamshidi M, Kazemi M, Kargar H, Sadeghi T. Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial. Ther Apher Dial 2023.

See these in context on the Valerian monograph →

Cinchona 15 references
  1. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  2. Wichtl MW. Herbal Drugs and Phytopharmaceuticals. Ed. N.M. Bisset. Stuttgart: Medpharm GmbH Scientific Publishers, 1994.
  3. Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York, NY: John Wiley & Sons, 1996.
  4. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
  5. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  6. Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  7. Holt GA. Food & Possible Interactions with Drugs: Revised and Expanded Ed. Chicago, IL: Precept Press, 1998.
  8. Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
  9. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics Inc., 1997 and updates.
  10. Amabeoku GJ, Chikuni O, Akino C, Mutetwa S. Pharmacokinetic interaction of single doses of quinine and carbamazepine, phenobarbitone and phenytoin in healthy volunteers. East Afr Med J 1993;70:90-3.
  11. Shah BH, Nawaz Z, Virani SS, Ali IQ, Saeed SA, Gilani AH.The inhibitory effect of cinchonine on human platelet aggregation due to blockade of calcium influx. Biochem Pharmacol 1998;56:955-60. PubMed
  12. US Food and Drug Administration notice: Drug products containing quinine - enforcement action dates. Docket # 2006N-0476. Federal Register 2006 (December 15);71 (241): 75557-60.
  13. FDA Drug Safety Communication: New risk management plan and patient medication guide for Qualaquin (quinine sulfate). 07-08-2010. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202 (accessed 02/18/17).
  14. Dooms-Goossens A, Deveylder H, Duron C, et al. Airborne contact urticaria due to cinchona. Contact Dermatitis 1986;15(4):258. PubMed
  15. Bramer SL, Suri A. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:41-51. PubMed

See these in context on the Cinchona monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring